{"id":38787,"date":"2023-07-10T11:49:28","date_gmt":"2023-07-10T09:49:28","guid":{"rendered":"https:\/\/kapitalpartner.dk\/?p=38787"},"modified":"2023-07-10T11:49:29","modified_gmt":"2023-07-10T09:49:29","slug":"saniona-still-the-one-to-beat-danish-biotech-weekly-28","status":"publish","type":"post","link":"https:\/\/kapitalpartner.dk\/en\/saniona-still-the-one-to-beat-danish-biotech-weekly-28\/","title":{"rendered":"Saniona still the one to beat: Danish Biotech Weekly (28)"},"content":{"rendered":"\n

Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc. <\/em><\/p>\n\n\n\n

In the past week, FluoGuide completed a 15 MSEK directed share issue, Zealand Pharma announced positive phase 1 results while Initiator Pharma finalized its buyback programme. Notably, Scandion Oncology rose nearly 50% without announcing any news.<\/strong><\/p>\n\n\n\n

Only 4 of the 20 listed, Danish biotech companies published news the past week. 7 of the 20 companies had a positive development in their share price for the week and 6 companies have had a positive share price performance year to date. Saniona continues to be the best performing stock this year with a price increase of more than 150%<\/strong>.<\/p>\n\n\n\n

\n
Register for the Danish Biotech Weekly newsletter<\/strong><\/a><\/div>\n<\/div>\n\n\n\n

<\/p>\n\n\n\n

Company news the past week<\/strong><\/p>\n\n\n\n

Ascendis Pharma<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Biosergen<\/strong><\/a><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Cessatech<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

CS Medica<\/strong><\/a><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Curasight<\/strong><\/a><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Evaxion Biotech<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Expres2ion<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Fluoguide<\/strong><\/p>\n\n\n\n

FluoGuide completes a directed share issue raising SEK 15 million (Link<\/a>)<\/p>\n\n\n\n

Genmab<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Gubra<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Initiator Pharma<\/strong><\/p>\n\n\n\n

Finalization of share buyback program in Initiator Pharma (Link<\/a>)<\/p>\n\n\n\n

IO Biotech<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/p>\n\n\n\n

Pila Pharma<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/p>\n\n\n\n

Saniona<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Scandion Oncology<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/p>\n\n\n\n

SynAct Pharma<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

ViroGates<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Zealand Pharma<\/strong><\/p>\n\n\n\n

Zealand Pharma announces positive results from Part 1 of multiple ascending dose trial with amylin analog ZP8396 (Link<\/a>)<\/p>\n\n\n\n

Y-mAbs Therapeutics<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

2cureX<\/strong><\/p>\n\n\n\n

Invitation to 2cureX Q2 update and Q&A session on July 12, 2023 at 20.00 (CET)<\/em><\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

SELECTED CASES<\/strong><\/p>\n\n\n\n

\n
\n

Biosergen<\/a><\/strong><\/h2>\n\n\n\n
\n\n\n\n
\"\"<\/a><\/figure>\n\n\n\n
\n
Investment case<\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n
\n

Curasight<\/a><\/strong><\/h2>\n\n\n\n
\n\n\n\n
\"\"<\/a><\/figure>\n\n\n\n
\n
Investment Case<\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n
\n

CS Medica<\/a><\/strong><\/h2>\n\n\n\n
\n\n\n\n
\"\"<\/a><\/figure>\n\n\n\n
\n
Investment case<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n

<\/p>\n\n\n\n

\n
Interested in Nordic healthcare stocks? View our weekly Nordic newsletter here (in Danish)<\/a><\/div>\n<\/div>\n\n\n\n

<\/p>\n\n\n\n

SHARE PRICE DEVELOPMENTS<\/strong><\/p>\n\n\n\n

On average, the Danish biotech stocks delivered a positive share price performance last week of 1.9%. The overall positive return was largely driven by Scandion Oncology <\/strong>that became the best performing stock with an 49% increase without announcing any company specific news. FluoGuide<\/strong> completed a directed share issue of 15 MSEK while Zealand Pharma<\/strong> announced positive phase 1 results for ZP8936 with potential against obesity and diabetes. Neither news had any significant effect on the share prices of the two companies. Curasight<\/strong> became the worst performing Danish biotech stock with a 9% decrease after a strong share price performance. The best stocks year-to-date include Curasight A\/S, Fluoguide A\/S, and Saniona AB<\/strong> after soaring 112-152%. Overall the Danish biotech stocks are in positive terrotory this year with a year-to-date return of 4.5%<\/strong>.<\/p>\n\n\n\n

Read more about Curasight and Fluoguide:<\/strong><\/mark> The unique cancer treatment of the future – Today’s investment<\/a><\/p>\n\n\n\n

Overview of share price developments the past week, year-to-date and last twelve months<\/strong><\/p>\n\n\n\n

\"\"<\/figure>\n","protected":false},"excerpt":{"rendered":"

Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc. In the past week, FluoGuide completed a 15 MSEK directed share issue, Zealand Pharma announced positive phase 1 results while Initiator Pharma finalized its […]<\/p>\n","protected":false},"author":11,"featured_media":37397,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[29,113],"tags":[],"class_list":["post-38787","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-investeringscases","category-sektorcases"],"acf":[],"yoast_head":"\nSaniona still the one to beat: Danish Biotech Weekly (28) | Kapital Partner A\/S<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kapitalpartner.dk\/en\/saniona-still-the-one-to-beat-danish-biotech-weekly-28\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Saniona still the one to beat: Danish Biotech Weekly (28) | Kapital Partner A\/S\" \/>\n<meta property=\"og:description\" content=\"Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc. In the past week, FluoGuide completed a 15 MSEK directed share issue, Zealand Pharma announced positive phase 1 results while Initiator Pharma finalized its […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kapitalpartner.dk\/en\/saniona-still-the-one-to-beat-danish-biotech-weekly-28\/\" \/>\n<meta property=\"og:site_name\" content=\"Kapital Partner A\/S\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/kapitalpartner\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-10T09:49:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-10T09:49:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1015\" \/>\n\t<meta property=\"og:image:height\" content=\"533\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Anders S\u00f8ndergaard\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:site\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Anders S\u00f8ndergaard\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/saniona-still-the-one-to-beat-danish-biotech-weekly-28\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/saniona-still-the-one-to-beat-danish-biotech-weekly-28\/\"},\"author\":{\"name\":\"Anders S\u00f8ndergaard\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed\"},\"headline\":\"Saniona still the one to beat: Danish Biotech Weekly (28)\",\"datePublished\":\"2023-07-10T09:49:28+00:00\",\"dateModified\":\"2023-07-10T09:49:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/saniona-still-the-one-to-beat-danish-biotech-weekly-28\/\"},\"wordCount\":487,\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/saniona-still-the-one-to-beat-danish-biotech-weekly-28\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\",\"articleSection\":[\"Investeringscases\",\"Sektorcases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/saniona-still-the-one-to-beat-danish-biotech-weekly-28\/\",\"url\":\"https:\/\/kapitalpartner.dk\/en\/saniona-still-the-one-to-beat-danish-biotech-weekly-28\/\",\"name\":\"Saniona still the one to beat: Danish Biotech Weekly (28) | Kapital Partner A\/S\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/saniona-still-the-one-to-beat-danish-biotech-weekly-28\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/saniona-still-the-one-to-beat-danish-biotech-weekly-28\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\",\"datePublished\":\"2023-07-10T09:49:28+00:00\",\"dateModified\":\"2023-07-10T09:49:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/saniona-still-the-one-to-beat-danish-biotech-weekly-28\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/kapitalpartner.dk\/en\/saniona-still-the-one-to-beat-danish-biotech-weekly-28\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/saniona-still-the-one-to-beat-danish-biotech-weekly-28\/#primaryimage\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\",\"width\":1015,\"height\":533},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/saniona-still-the-one-to-beat-danish-biotech-weekly-28\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investeringscases\",\"item\":\"https:\/\/kapitalpartner.dk\/category\/investeringscases\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Sektorcases\",\"item\":\"https:\/\/kapitalpartner.dk\/category\/investeringscases\/sektorcases\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Saniona still the one to beat: Danish Biotech Weekly (28)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/kapitalpartner.dk\/#website\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"name\":\"Kapital Partner A\/S\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/kapitalpartner.dk\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\",\"name\":\"Kapital Partner A\/S\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"width\":496,\"height\":432,\"caption\":\"Kapital Partner A\/S\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/kapitalpartner\",\"https:\/\/x.com\/KapitalPartner\",\"https:\/\/www.linkedin.com\/company\/10438322\",\"https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed\",\"name\":\"Anders S\u00f8ndergaard\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g\",\"caption\":\"Anders S\u00f8ndergaard\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Saniona still the one to beat: Danish Biotech Weekly (28) | Kapital Partner A\/S","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kapitalpartner.dk\/en\/saniona-still-the-one-to-beat-danish-biotech-weekly-28\/","og_locale":"en_US","og_type":"article","og_title":"Saniona still the one to beat: Danish Biotech Weekly (28) | Kapital Partner A\/S","og_description":"Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc. In the past week, FluoGuide completed a 15 MSEK directed share issue, Zealand Pharma announced positive phase 1 results while Initiator Pharma finalized its […]","og_url":"https:\/\/kapitalpartner.dk\/en\/saniona-still-the-one-to-beat-danish-biotech-weekly-28\/","og_site_name":"Kapital Partner A\/S","article_publisher":"https:\/\/www.facebook.com\/kapitalpartner","article_published_time":"2023-07-10T09:49:28+00:00","article_modified_time":"2023-07-10T09:49:29+00:00","og_image":[{"width":1015,"height":533,"url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","type":"image\/png"}],"author":"Anders S\u00f8ndergaard","twitter_card":"summary_large_image","twitter_creator":"@KapitalPartner","twitter_site":"@KapitalPartner","twitter_misc":{"Written by":"Anders S\u00f8ndergaard","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kapitalpartner.dk\/en\/saniona-still-the-one-to-beat-danish-biotech-weekly-28\/#article","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/en\/saniona-still-the-one-to-beat-danish-biotech-weekly-28\/"},"author":{"name":"Anders S\u00f8ndergaard","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed"},"headline":"Saniona still the one to beat: Danish Biotech Weekly (28)","datePublished":"2023-07-10T09:49:28+00:00","dateModified":"2023-07-10T09:49:29+00:00","mainEntityOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/saniona-still-the-one-to-beat-danish-biotech-weekly-28\/"},"wordCount":487,"publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/saniona-still-the-one-to-beat-danish-biotech-weekly-28\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","articleSection":["Investeringscases","Sektorcases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/kapitalpartner.dk\/en\/saniona-still-the-one-to-beat-danish-biotech-weekly-28\/","url":"https:\/\/kapitalpartner.dk\/en\/saniona-still-the-one-to-beat-danish-biotech-weekly-28\/","name":"Saniona still the one to beat: Danish Biotech Weekly (28) | Kapital Partner A\/S","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/saniona-still-the-one-to-beat-danish-biotech-weekly-28\/#primaryimage"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/saniona-still-the-one-to-beat-danish-biotech-weekly-28\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","datePublished":"2023-07-10T09:49:28+00:00","dateModified":"2023-07-10T09:49:29+00:00","breadcrumb":{"@id":"https:\/\/kapitalpartner.dk\/en\/saniona-still-the-one-to-beat-danish-biotech-weekly-28\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kapitalpartner.dk\/en\/saniona-still-the-one-to-beat-danish-biotech-weekly-28\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/en\/saniona-still-the-one-to-beat-danish-biotech-weekly-28\/#primaryimage","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","width":1015,"height":533},{"@type":"BreadcrumbList","@id":"https:\/\/kapitalpartner.dk\/en\/saniona-still-the-one-to-beat-danish-biotech-weekly-28\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kapitalpartner.dk\/en\/"},{"@type":"ListItem","position":2,"name":"Investeringscases","item":"https:\/\/kapitalpartner.dk\/category\/investeringscases\/"},{"@type":"ListItem","position":3,"name":"Sektorcases","item":"https:\/\/kapitalpartner.dk\/category\/investeringscases\/sektorcases\/"},{"@type":"ListItem","position":4,"name":"Saniona still the one to beat: Danish Biotech Weekly (28)"}]},{"@type":"WebSite","@id":"https:\/\/kapitalpartner.dk\/#website","url":"https:\/\/kapitalpartner.dk\/","name":"Kapital Partner A\/S","description":"","publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kapitalpartner.dk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/kapitalpartner.dk\/#organization","name":"Kapital Partner A\/S","url":"https:\/\/kapitalpartner.dk\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","width":496,"height":432,"caption":"Kapital Partner A\/S"},"image":{"@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/kapitalpartner","https:\/\/x.com\/KapitalPartner","https:\/\/www.linkedin.com\/company\/10438322","https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w"]},{"@type":"Person","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed","name":"Anders S\u00f8ndergaard","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g","caption":"Anders S\u00f8ndergaard"}}]}},"_links":{"self":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/38787"}],"collection":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/comments?post=38787"}],"version-history":[{"count":1,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/38787\/revisions"}],"predecessor-version":[{"id":38788,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/38787\/revisions\/38788"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media\/37397"}],"wp:attachment":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media?parent=38787"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/categories?post=38787"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/tags?post=38787"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}